EP3628319
MEÐFERÐ VIÐ LIFRARHEILAKVILLA MEÐ RIFAXIMÍNI
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
2.10.2009EP published:
14.2.2024EP application number:
19207534.9
EP translation filed:
6.3.2024Grant published:
15.4.2024EPO information:
European Patent Register
Max expiry date:
1.10.2029Expiry date:
1.10.2026Next due date:
31.10.2026
Title in English:
TREATMENT OF HEPATIC ENCEPHALOPATHY USING RIFAXIMINLanguage of the patent:
English
Timeline
Today
2.10.2009EP application
14.2.2024EP Publication
6.3.2024Translation submitted
15.4.2024Registration published
1.10.2026Expires
Owner
Name:
Salix Pharmaceuticals, Inc.Address:
400 Somerset Corporate Blvd., Bridgewater, New Jersey 08807, US
Inventor
Name:
FORBES, WilliamAddress:
Raleigh, NC 27164, US
Agent
Name:
Novagraaf BrevetsAddress:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
Priority
Number:
102349 PDate:
2.10.2008Country:
US
Classification
Categories:
A61K 31/437, A61K 45/06, A61K 31/08, A61K 31/352, A61K 31/4164, A61K 31/426, A61K 31/4439, A61K 31/606, A61K 31/7016, A61K 31/785, A61K 38/14, A61K 38/31, A61P 1/16, A61K 31/395
Annual fees
Number
Paid
Expires
Payer
Number: 16
Paid: 17.9.2024
Expires: 1.10.2025
Payer: Árnason Faktor ehf.
Number: 17
Paid: 17.9.2025
Expires: 1.10.2026
Payer: Árnason Faktor ehf.